Attenuation of Portal Hypertension by Continuous Portal Infusion of PGE1 and Immunologic Impact in Adult-to-Adult Living-Donor Liver Transplantation

2013 ◽  
Vol 95 (12) ◽  
pp. 1521-1527 ◽  
Author(s):  
Takashi Onoe ◽  
Yuka Tanaka ◽  
Kentaro Ide ◽  
Kouhei Ishiyama ◽  
Akihiko Oshita ◽  
...  
2020 ◽  
Vol 104 (S3) ◽  
pp. S495-S496
Author(s):  
Takashi Onoe ◽  
Shinji Hashimoto ◽  
Masataka Banshodani ◽  
Kazuhiro Taguchi ◽  
Yuka Tanaka ◽  
...  

2016 ◽  
Vol 100 (10) ◽  
pp. 2138-2145 ◽  
Author(s):  
Kazuyuki Gyoten ◽  
Shugo Mizuno ◽  
Hiroyuki Kato ◽  
Yasuhiro Murata ◽  
Akihiro Tanemura ◽  
...  

2019 ◽  
Vol 203 (5) ◽  
pp. 1392-1403 ◽  
Author(s):  
Shinji Hashimoto ◽  
Takashi Onoe ◽  
Masataka Banshodani ◽  
Kazuhiro Taguchi ◽  
Yuka Tanaka ◽  
...  

Swiss Surgery ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 227-236 ◽  
Author(s):  
Majno ◽  
Mentha ◽  
Berney ◽  
Bühler ◽  
Giostra ◽  
...  

Living donor liver transplantation is a relatively new procedure in which the right side of the liver is harvested in a healthy donor and transplanted into a recipient. After the first case in 1994, over 3000 cases have been done worldwide. This review summarizes the reasons why the procedure is needed, describes its main technical aspects, highlights the boundaries in which it can be done safely, summarizes the current experience worldwide and describes the main points of the program in our unit. We argue that living-donor transplantation is a viable alternative to a long time on the waiting list for several patients, and it can be performed safely and successfully provided that all precautions are undertaken to minimize the risks in the donor and to increase the chances of a good outcome in the recipients. If these prerequisites are met, and within the framework of a structured multidisciplinary program, we believe that living-donor liver transplantation should be funded by health insurances as a recognized therapeutic option.


Sign in / Sign up

Export Citation Format

Share Document